- Home
- ATXS vs UROY Comparison
ATXS vs UROY Comparison
Compare ATXS & UROY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- UROY
- Stock Information
- Founded
- ATXS 2008
- UROY 2017
- Country
- ATXS United States
- UROY Canada
- Employees
- ATXS N/A
- UROY N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- UROY
- Sector
- ATXS Health Care
- UROY
- Exchange
- ATXS Nasdaq
- UROY Nasdaq
- Market Cap
- ATXS 401.2M
- UROY 336.8M
- IPO Year
- ATXS 2015
- UROY N/A
- Fundamental
- Price
- ATXS $6.85
- UROY $2.66
- Analyst Decision
- ATXS Buy
- UROY Strong Buy
- Analyst Count
- ATXS 6
- UROY 2
- Target Price
- ATXS $32.00
- UROY $4.00
- AVG Volume (30 Days)
- ATXS 248.4K
- UROY 3.2M
- Earning Date
- ATXS 08-12-2025
- UROY 08-26-2025
- Dividend Yield
- ATXS N/A
- UROY N/A
- EPS Growth
- ATXS N/A
- UROY N/A
- EPS
- ATXS N/A
- UROY N/A
- Revenue
- ATXS N/A
- UROY $11,285,840.00
- Revenue This Year
- ATXS N/A
- UROY $126.69
- Revenue Next Year
- ATXS N/A
- UROY N/A
- P/E Ratio
- ATXS N/A
- UROY N/A
- Revenue Growth
- ATXS N/A
- UROY N/A
- 52 Week Low
- ATXS $3.56
- UROY $1.43
- 52 Week High
- ATXS $12.92
- UROY $3.30
- Technical
- Relative Strength Index (RSI)
- ATXS 56.47
- UROY 51.35
- Support Level
- ATXS $6.60
- UROY $2.53
- Resistance Level
- ATXS $7.20
- UROY $2.71
- Average True Range (ATR)
- ATXS 0.47
- UROY 0.14
- MACD
- ATXS -0.03
- UROY -0.02
- Stochastic Oscillator
- ATXS 61.72
- UROY 43.64
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is the investment in a portfolio of uranium interests.